# US 2010/0166782 A1 · Clip inhibitors and methods of modulating immune function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166782 A1
- Document ID: US20100166782A1
- Status: Published application
- Kind: A1
- Application number: 12/508,543
- Filed: 2009-07-23
- Published: 2010-07-01
- Earliest claimed: 2008-07-25
- Inventors: Martha Karen Newell; Evan Newell; Haig Keledjian; Michael Agadjanyan
- Web page: https://patentgrep.com/patent/US20100166782A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, allergic disease transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS.

## Claims

### Claim 1

A composition comprising
an isolated MHC class II CLIP inhibitor comprising a peptide of SEQ ID NO 49, 58, 59, 61, 62, 66, 67, 68, 69, 76, 77, 78, 81, 82, 86, 89, 90, 92, 104, 109, 110, 112, 117, 128, 129, 133, 136, 140, 141, 144, 146, 148, 149, 150, 154, 156, 157, 161, 162, 164, 168, 171, 172, 175, 177, 179, 186, 187, 188, 190, 191, 192, 196, 197, 201, 204, 205, 210, 217, 218, 220, 221, 222, 226, 227, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, or a variant thereof and a carrier.

### Claim 2 (depends on 1)

The composition of claim 1, wherein MHC class II CLIP inhibitor is synthetic.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising an adjuvant.

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 1)

The composition of claim 1, further comprising an anti-HIV agent.

### Claim 8

(canceled)

### Claim 9

A method of treatment for HIV infection comprising administering to a human infected with HIV or at risk of HIV infection a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The method of claim 9, wherein CLIP inhibitor is a MHC class II CLIP inhibitor.

### Claim at position 9

-14. (canceled)

### Claim 15 (depends on 9)

The method according to claim 9, wherein the CLIP inhibitor is a peptide of any of SEQ ID NO. 49, 58, 59, 61, 62, 66, 67, 68, 69, 76, 77, 78, 81, 82, 86, 89, 90, 92, 104, 109, 110, 112, 117, 128, 129, 133, 136, 140, 141, 144, 146, 148, 149, 150, 154, 156, 157, 161, 162, 164, 168, 171, 172, 175, 177, 179, 186, 187, 188, 190, 191, 192, 196, 197, 201, 204, 205, 210, 217, 218, 220, 221, 222, 226, 227, 307, and 308.

### Claim at position 11

-29. (canceled)

### Claim 30

A method for treating a viral infection comprising administering to a subject infected with a virus or at risk of a viral infection a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 30)

The method of claim 30, wherein CLIP inhibitor is a MHC class II CLIP inhibitor.

### Claim 32 (depends on 30)

The method of claim 30 wherein the subject is infected with Borrelia burgdorferi.

### Claim 33 (depends on 30)

The method of claim 30 wherein the subject is infected with hepatitis virus.

### Claim 34 (depends on 30)

The method of claim 30 wherein the subject is infected with herpes virus.

### Claim 35 (depends on 30)

The method of claim 30 wherein the subject is infected with CMV.

### Claim 36 (depends on 30)

The method of claim 30 wherein the subject is infected with EBV.

### Claim at position 19

-42. (canceled)

### Claim 43

A method for treating a cancer comprising administering to a subject having a cancer a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.

### Claim 44 (depends on 43)

The method of claim 43, wherein CLIP inhibitor is a MHC class I CLIP inhibitor.

### Claim 45 (depends on 43)

The method of claim 43, further comprising adminstering a cancer antigen.

### Claim at position 23

-48. (canceled)

### Claim 49

A method for treating an autoimmune disease comprising administering to a subject having autoimmune disease a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.

### Claim at position 25

-55. (canceled)

### Claim 56

A method for treating an allergic disease comprising administering to a subject having allergic disease a composition comprising a CLIP inhibitor and a pharmaceutically acceptable carrier.

### Claim at position 27

-58. (canceled)

### Claim 59

A peptide having a peptide sequence corresponding to any one of SEQ ID NOs. 49, 58, 59, 61, 62, 66, 67, 68, 69, 76, 77, 78, 81, 82, 86, 89, 90, 92, 104, 109, 110, 112, 117, 128, 129, 133, 136, 140, 141, 144, 146, 148, 149, 150, 154, 156, 157, 161, 162, 164, 168, 171, 172, 175, 177, 179, 186, 187, 188, 190, 191, 192, 196, 197, 201, 204, 205, 210, 217, 218, 220, 221, 222, 226, 227, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, and 324.

### Claim 60 (depends on 59)

A method of treating HIV, comprising administering to a subject a peptide of claim 59.

### Claim 61

A method for identifying a subject sensitive to treatment with a CLIP inhibitor, comprising, determining an MHC class I or II allele of the subject and determining a predicted binding value of the peptide for the MHC class I or II allele of the subject, wherein a predicted binding value greater than the predicted binding value of CLIP for MHC class I or II allele is indicative of whether a CLIP inhibitor is effective for displacing CLIP from the MHC class I or II allele of the subject and is a CLIP inhibitor for the subject.

### Claim 62

A method of treating a subject with a CLIP inhibitor, comprising, determining an MHC class I or II allele of a subject and administering to the subject a CLIP inhibitor in an effective amount to displace CLIP from a surface of a cell.

### Claim 63 (depends on 62)

The method of claim 62, wherein, if the allele is DR2, the CLIP inhibitor is a peptide of SEQ ID NO 290, 291, or 292.

### Claim 64 (depends on 63)

The method of claim 63, wherein the subject is suspected of having Tuberculosis.

### Claim 65 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1*1301, the CLIP inhibitor is a peptide of SEQ ID NO 293 or 294.

### Claim 66 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0301, the CLIP inhibitor is a peptide of SEQ ID NO 295 or 296.

### Claim 67 (depends on 65)

The method of claim 65, wherein the subject is suspected of having Hepatitis C.

### Claim 68 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0101 or DRB1—0401, the CLIP inhibitor is a peptide of SEQ ID NO 297.

### Claim 69 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0404, the CLIP inhibitor is a peptide of SEQ ID NO 298.

### Claim 70 (depends on 62)

The method of claim 62, wherein, if the allele is DRB 1—0405, the CLIP inhibitor is a peptide of SEQ ID NO 299.

### Claim at position 40

-72. (canceled)

### Claim 73 (depends on 62)

The method of claim 62, wherein, if the allele is B*4601, the CLIP inhibitor is a peptide of SEQ ID NO 300 or 301.

### Claim 74

(canceled)

### Claim 75 (depends on 62)

The method of claim 62, wherein, if the allele is HLA E*0101, the CLIP inhibitor is a peptide of SEQ ID NO 302 or 303.

### Claim 76 (depends on 75)

The method of claim 75, wherein the subject is suspected of having Bacterial Meningitis.

### Claim 77 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0401, the CLIP inhibitor is a peptide of SEQ ID NO 304.

### Claim 78

(canceled)

### Claim 79 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0401, the CLIP inhibitor is a peptide of SEQ ID NO 305.

### Claim 80

(canceled)

### Claim 81 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1*0401, the CLIP inhibitor is a peptide of SEQ ID NO 306.

### Claim 82

(canceled)

### Claim 83 (depends on 62)

The method of claim 62, wherein, if the allele is B3501, the CLIP inhibitor is a peptide of SEQ ID NO 307 or 308.

### Claim 84

(canceled)

### Claim 85 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0901, the CLIP inhibitor is a peptide of SEQ ID NO 309.

### Claim 86 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0301, the CLIP inhibitor is a peptide of SEQ ID NO 310.

### Claim 87

(canceled)

### Claim 88 (depends on 62)

The method of claim 62, wherein, if the allele is B2705, the CLIP inhibitor is a peptide of SEQ ID NO 311 or 312.

### Claim 89

(canceled)

### Claim 90 (depends on 62)

The method of claim 62, wherein, if the allele is A0301, the CLIP inhibitor is a peptide of SEQ ID NO 313 or 314.

### Claim 91 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—1501, the CLIP inhibitor is a peptide of SEQ ID NO 315.

### Claim 92

(canceled)

### Claim 93 (depends on 62)

The method of claim 62, wherein, if the allele is B2705, the CLIP inhibitor is a peptide of SEQ ID NO 316.

### Claim 94

(canceled)

### Claim 95 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0301, the CLIP inhibitor is a peptide of SEQ ID NO 317.

### Claim 96 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0701, the CLIP inhibitor is a peptide of SEQ ID NO 318.

### Claim 97

(canceled)

### Claim 98 (depends on 62)

The method of claim 62, wherein, if the allele is B2705, the CLIP inhibitor is a peptide of SEQ ID NO 319 or 320.

### Claim 99 (depends on 62)

The method of claim 62, wherein, if the allele is B3901, the CLIP inhibitor is a peptide of SEQ ID NO 321 or 322.

### Claim 100

(canceled)

### Claim 101 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0701, the CLIP inhibitor is a peptide of SEQ ID NO 323.

### Claim 102 (depends on 62)

The method of claim 62, wherein, if the allele is DRB1—0802, the CLIP inhibitor is a peptide of SEQ ID NO 324.

### Claim at position 71

-108. (canceled)

### Claim 109

A method of treatment for Lyme disease comprising administering to a human suspected of having Lyme disease a composition comprising a peptide comprising a sequence as set forth in SEQ ID NO 304 and a pharmaceutically acceptable carrier.

### Claim at position 73

-117. (canceled)

### Claim 118

A method of treatment for cancer comprising administering to a human suspected of having cancer a Toll Ligand Receptor (TLR) agonist, wherein the TLR is TLR2, TLR 7/8, TLR4, or TLR 9, and a CLP inhibitor in an effective amount to displace CLIP from a surface of a cell.

### Claim at position 75

-120. (canceled)
